DEVELOPMENT OF STIMULI-RESPONSIVE NANOCARRIERS FOR CONTROLLED DRUG RELEASE

Authors

  • Dr. Lucas M. Reynolds Department of Molecular and Cellular Biology, Center for Advanced Biomedical Studies, USA

Keywords:

stimuli-responsive nanocarriers; controlled drug release; smart drug delivery; pH-responsive nanoparticles; redox-responsive systems; enzyme-responsive delivery; ultrasound-triggered release; nanomedicine.

Abstract

Stimuli-responsive nanocarriers are engineered delivery systems that translate disease-associated biochemical signals or externally applied physical energy into controlled changes in carrier structure, permeability, charge, or chemical bonding. These systems are intended to reduce premature drug leakage, increase drug exposure at the desired site, and provide temporal control over therapeutic release. This structured review evaluates current strategies for pH-, redox-, reactive oxygen species (ROS)-, enzyme-, hypoxia-, temperature-, light-, ultrasound-, and magnetic-field-responsive nanocarriers, with emphasis on release mechanisms, material choices, translational advantages, and failure modes. Literature was synthesized from peer-reviewed international sources with priority given to mechanistic reviews and recent translational analyses. The evidence indicates that endogenous triggers can exploit pathological gradients without external equipment, whereas exogenous triggers provide stronger spatiotemporal control but depend on energy penetration and device accessibility. Multi-stimuli systems may improve selectivity, although design complexity can impair reproducibility, manufacturability, pharmacokinetic predictability, and regulatory assessment. Recent clinical-landscape analyses also show a major gap between the volume of preclinical publications and routine clinical use. Rational development should therefore prioritize a clinically meaningful trigger, robust stimulus-to-release contrast, simple and scalable chemistry, reproducible characterization, and early assessment of biodistribution and safety. Stimuli-responsive nanocarriers remain a powerful platform for precision drug delivery, but translation will depend on balancing mechanistic sophistication with pharmaceutical practicality.

 

References

1. Mura, S., Nicolas, J., & Couvreur, P. (2013). Stimuli-responsive nanocarriers for drug delivery. Nature Materials, 12(11), 991–1003. https://doi.org/10.1038/nmat3776

2. Mi, P. (2020). Stimuli-responsive nanocarriers for drug delivery, tumor imaging, therapy and theranostics. Theranostics, 10(10), 4557–4588. https://doi.org/10.7150/thno.38069

3. Shinn, J., Kwon, N., Lee, S. A., & Lee, Y. (2022). Smart pH-responsive nanomedicines for disease therapy. Journal of Pharmaceutical Investigation, 52(4), 427–441. https://doi.org/10.1007/s40005-022-00573-z

4. Zhou, W., Jia, Y., Liu, Y., Chen, Y., & Zhao, P. (2022). Tumor microenvironment-based stimuli-responsive nanoparticles for controlled release of drugs in cancer therapy. Pharmaceutics, 14(11), 2346. https://doi.org/10.3390/pharmaceutics14112346

5. Luo, S., Lv, Z., Yang, Q., Chang, R., & Wu, J. (2023). Research progress on stimulus-responsive polymer nanocarriers for cancer treatment. Pharmaceutics, 15(7), 1928. https://doi.org/10.3390/pharmaceutics15071928

6. Kapalatiya, H., Madav, Y., Tambe, V. S., & Wairkar, S. (2022). Enzyme-responsive smart nanocarriers for targeted chemotherapy: An overview. Drug Delivery and Translational Research, 12(6), 1293–1305. https://doi.org/10.1007/s13346-021-01020-6

7. Mollazadeh, S., Mackiewicz, M., & Yazdimamaghani, M. (2021). Recent advances in the redox-responsive drug delivery nanoplatforms: A chemical structure and physical property perspective. Materials Science and Engineering: C, 118, 111536. https://doi.org/10.1016/j.msec.2020.111536

8. Bordat, A., Boissenot, T., Nicolas, J., & Tsapis, N. (2019). Thermoresponsive polymer nanocarriers for biomedical applications. Advanced Drug Delivery Reviews, 138, 167–192. https://doi.org/10.1016/j.addr.2018.10.005

9. Zhao, W., Zhao, Y., Wang, Q., Liu, T., Sun, J., & Zhang, R. (2019). Remote light-responsive nanocarriers for controlled drug delivery: Advances and perspectives. Small, 15(45), e1903060. https://doi.org/10.1002/smll.201903060

10. Al Refaai, K. A., AlSawaftah, N. A., Abuwatfa, W., & Husseini, G. A. (2024). Drug release via ultrasound-activated nanocarriers for cancer treatment: A review. Pharmaceutics, 16(11), 1383. https://doi.org/10.3390/pharmaceutics16111383

11. Xia, Y., Duan, S., Han, C., Jing, C., Xiao, Z., & Li, C. (2022). Hypoxia-responsive nanomaterials for tumor imaging and therapy. Frontiers in Oncology, 12, 1089446. https://doi.org/10.3389/fonc.2022.1089446

12. Tian, M., Xin, X., Wu, R., Guan, W., & Zhou, W. (2022). Advances in intelligent-responsive nanocarriers for cancer therapy. Pharmacological Research, 178, 106184. https://doi.org/10.1016/j.phrs.2022.106184

13. Shaik, B. B., Katari, N. K., & Jonnalagadda, S. B. (2023). Internal stimuli-responsive nanocarriers for controlled anti-cancer drug release: A review. Therapeutic Delivery, 14(9), 595–613. https://doi.org/10.4155/tde-2023-0041

14. Saravanakumar, K., Hu, X., Ali, D. M., & Wang, M.-H. (2019). Emerging strategies in stimuli-responsive nanocarriers as the drug delivery system for enhanced cancer therapy. Current Pharmaceutical Design, 25(24), 2609–2625. https://doi.org/10.2174/1381612825666190709221141

Published

2026-09-21